Scientific Sessions 2024  /  Featured Science: Vascular Outcomes in the Spotlight  /  Evolution of Novel Therapies in Vascular Medicine
Logo

American Heart Association

  180
  0

Final ID:

Evolution of Novel Therapies in Vascular Medicine

  • Creager, Mark  ( Dartmouth-Hitchcock , Lebanon , New Hampshire , United States )
  • Beckman, Joshua  ( UT Southwestern , Dallas , Texas , United States )
    • Author Disclosures:
    Mark Creager: DO NOT have relevant financial relationships | Joshua Beckman: DO have relevant financial relationships ; Consultant:Janssen:Past (completed) ; Consultant:Merck:Active (exists now) ; Consultant:Antidote Therapeutics:Active (exists now) ; Consultant:Mingsight:Active (exists now) ; Consultant:JanOne:Active (exists now) ; Consultant:Novartis:Active (exists now)
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

Featured Science: Vascular Outcomes in the Spotlight

Monday, 11/18/2024 , 08:00AM - 09:15AM

Featured Science

More abstracts on this topic:
Rivaroxaban for 18 Months versus 6 Months in Cancer Patients with Low-risk Pulmonary Embolism: ONCO PE Trial

Yamashita Yugo, Morimoto Takeshi, Muraoka Nao, Shioyama Wataru, Chatani Ryuki, Shibata Tatsuhiro, Nishimoto Yuji, Ono Koh, Kimura Takeshi

Discussant: ONCO PE Trial

Kadian Daniella, Casanegra Ana, Okwuosa Tochi

More abstracts from these authors:
Antithrombotic prophylaxis in patients with peripheral arterial disease

Bonaca Marc, Creager Mark

Rural and Urban Patterns of Monitoring of Implanted Cardiac Devices in the US

Zeitler Emily, Zhou Weiping, Creager Mark, O'malley James

You have to be authorized to contact abstract author. Please, Login
Not Available